Business Description
Landos Biopharma Inc
NAICS : 541714
SIC : 2833
1800 Kraft Drive, Suite 216, Blacksburg, VA, USA, 24060
Description
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2733.19 | |||||
| Equity-to-Asset | 0.8 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -0.97 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -58.5 | |||||
| 3-Year EPS without NRI Growth Rate | -57.3 | |||||
| 3-Year FCF Growth Rate | -34.6 | |||||
| 3-Year Book Growth Rate | 256 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.09 | |||||
| 9-Day RSI | 54.82 | |||||
| 14-Day RSI | 56.46 | |||||
| 6-1 Month Momentum % | -60.69 | |||||
| 12-1 Month Momentum % | -94.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.99 | |||||
| Quick Ratio | 4.99 | |||||
| Cash Ratio | 4.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -243.72 | |||||
| Net Margin % | -241.49 | |||||
| ROE % | -49.5 | |||||
| ROA % | -43.12 | |||||
| ROIC % | -6118.55 | |||||
| ROC (Joel Greenblatt) % | -8007.3 | |||||
| ROCE % | -49.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.35 | |||||
| PB Ratio | 0.69 | |||||
| Price-to-Tangible-Book | 0.69 | |||||
| EV-to-EBIT | 0.71 | |||||
| EV-to-EBITDA | 0.72 | |||||
| EV-to-Revenue | -1.73 | |||||
| EV-to-FCF | 0.99 | |||||
| Price-to-Net-Current-Asset-Value | 0.69 | |||||
| Price-to-Net-Cash | 0.73 | |||||
| Earnings Yield (Greenblatt) % | 140.85 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:LABP
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18 | ||
| EPS (TTM) ($) | -1.39 | ||
| Beta | 0 | ||
| Volatility % | 77.46 | ||
| 14-Day RSI | 56.46 | ||
| 14-Day ATR ($) | 0.125476 | ||
| 20-Day SMA ($) | 0.9388 | ||
| 12-1 Month Momentum % | -94.03 | ||
| 52-Week Range ($) | 0.5501 - 16.17 | ||
| Shares Outstanding (Mil) | 40.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Landos Biopharma Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||